Up to 80 percent of individuals living with long-term type 1 diabetes experience gastrointestinal symptoms such as abdominal distension, irritable bowel syndrome, and fecal incontinence. A study reveals why these symptoms arise and tests an investigational drug in mice that could prevent them from developing.